Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 8NETWORK 4NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Prostatic Neoplasms 102Lymphoma, Large B-Cell, Diffuse 32Neoplasms 22Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 20Lymphoma 19Multiple Myeloma 15Lymphoma, B-Cell 11Neoplasm Metastasis 10Recurrence 8Lymphoma, T-Cell, Peripheral 7Prostatic Neoplasms, Castration-Resistant 5Prostate Cancer Metastatic 5Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Mantle-Cell 5Hematologic Diseases 5Lymphoma, B-Cell, Marginal Zone 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Leukemia, Lymphocytic, Chronic, B-Cell 3Triple Negative Breast Neoplasms 2Pain 2Metastatic Castration Resistant Prostate Cancer 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia 2Graft vs Host Disease 2Endometrial Neoplasms 2

Interventions

Rituximab 3Brentuximab Vedotin 2venetoclax 1veltuzumab 1pirtobrutinib 1ontuxizumab 1iratumumab 1exatecan 1durvalumab 1Zidovudine 1Vincristine 1RFB4(dsFv)-PE38 recombinant immunotoxin 1Prednisone 1Prednisolone 1Oxaliplatin 1Mitoxantrone 1Mannose-Binding Lectin 1Lenalidomide 1Gemcitabine 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bendamustine Hydrochloride 1Antibodies, Monoclonal 1Adrenal Cortex Hormones 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Dendritic Cell Sarcoma, Interdigitating × Prednisone × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡